Literature DB >> 29791948

Multiple Sclerosis.

Bassem I Yamout1, Raed Alroughani2.   

Abstract

Multiple sclerosis (MS) is a chronic central nervous system inflammatory disease of autoimmune etiology, mediated by activated T cells with evolving evidence of a significant contribution from B cells and cells of the innate immune system. The disease is thought to be due to a complex interaction between different genetic and environmental factors. The prevalence of MS is rising all over the world, due on one hand to earlier diagnosis and prolonged survival, and on the other to a true increase in incidence of the disease. The diagnosis of MS remains clinical despite recent advances in diagnostics and relies on demonstrating dissemination in space and time while excluding alternative diagnoses. The Mc Donald diagnostic criteria, with their recent 2017 revision, are currently widely accepted in the MS community. Although no cure is yet available, many disease-modifying therapies (DMTs) have shown different levels of efficacy in preventing relapses, accumulation of lesions on magnetic resonance imaging (MRI), and disability progression. Current treatment strategies include gradual escalation based on clinical and radiological criteria that determine treatment response, or initial induction with high efficacy DMTs especially in patients with an early aggressive course. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29791948     DOI: 10.1055/s-0038-1649502

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  36 in total

Review 1.  Deubiquitylating enzymes: potential target in autoimmune diseases.

Authors:  Niraj Parihar; Lokesh Kumar Bhatt
Journal:  Inflammopharmacology       Date:  2021-11-18       Impact factor: 4.473

2.  Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.

Authors:  Massimo Filippi; Federica Esposito; Miryam Cannizzaro; Laura Ferré; Ferdinando Clarelli; Antonino Giordano; Francesca Sangalli; Bruno Colombo; Giancarlo Comi; Lucia Moiola; Vittorio Martinelli
Journal:  J Neurol       Date:  2022-06-27       Impact factor: 6.682

Review 3.  MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.

Authors:  T P Nhung Nguyen; Mandeep Kumar; Ernesto Fedele; Giambattista Bonanno; Tiziana Bonifacino
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

Review 4.  Non-invasive Brain Stimulation for Central Neuropathic Pain.

Authors:  Qi-Hao Yang; Yong-Hui Zhang; Shu-Hao Du; Yu-Chen Wang; Yu Fang; Xue-Qiang Wang
Journal:  Front Mol Neurosci       Date:  2022-05-19       Impact factor: 6.261

5.  Newly Diagnosed Multiple Sclerosis Presenting as Brown-Séquard Syndrome: A Case Report.

Authors:  Shelby Hoebee; Levi Howard; James Komara; Megan McElhinny
Journal:  Clin Pract Cases Emerg Med       Date:  2022-05

6.  Development of a Prognostic Model for Predicting Multiple Sclerosis After Optic Neuritis: A Secondary Analysis of Data From the Optic Neuritis Treatment Trial.

Authors:  Wenjing Luo; Xinlei Deng; Xiaoyu Xu; Ruitong Song; Meifeng Luo; Heather E Moss; Yi Du
Journal:  J Neuroophthalmol       Date:  2021-10-22       Impact factor: 4.415

7.  Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis.

Authors:  J N Williams; C B Speyer; D J Kreps; D J Kimbrough; K Costenbader; S Bhattacharyya
Journal:  Lupus       Date:  2019-11-03       Impact factor: 2.911

8.  Trends in the Use of Sphingosine 1 Phosphate in Age-Related Diseases: A Scientometric Research Study (1992-2020).

Authors:  Qiong He; Gaofeng Ding; Mengyuan Zhang; Peng Nie; Jing Yang; Dong Liang; Jiaqi Bo; Yi Zhang; Yunfeng Liu
Journal:  J Diabetes Res       Date:  2021-02-25       Impact factor: 4.011

9.  ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.

Authors:  Farshid Mashayekhi; Saeed Sadigh-Eteghad; Amirreza Naseri; Milad Asadi; Negin Abbasi Garravnd; Mahnaz Talebi
Journal:  Neurol Sci       Date:  2021-06-12       Impact factor: 3.307

10.  Description and preliminary experience with Virtual Visit Assessment (ViVA) during the COVID-19 pandemic, a structured virtual management protocol for patients with multiple sclerosis.

Authors:  Roberto Bergamaschi; Livio Tronconi; Daniele Bosone; Antonella Mastretti; Laura Jommi; Marco Andrè Bassano; Renato Turrini; Sara Benati; Marco Volpe; Jean Marie Franzini; Silvia Allodi; Giulia Mallucci
Journal:  Neurol Sci       Date:  2021-06-15       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.